TrialUrolithiasis2018

A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.

Dawn Milliner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.